Daniel (Dan) Edelman, Ph.D.

Program Officer | Early Detection

Email: dan.edelman@nih.gov


Daniel Edelman, M.S., Ph.D., joined the Early Detection Research Group (EDRG) in the Division of Cancer Prevention (DCP) in November 2023 as a Program Officer/Health Scientist Administrator. Dr. Edelman primarily works on matters related to the Cancer Screening Research Network (CSRN), a new clinical trials network that will systematically evaluate different technologies related to cancer screening.

Before joining DCP, Dr. Edelman worked as a Policy Analyst for three years in the Food and Drug Administration (FDA) Office of In Vitro Diagnostics within the Center for Devices and Radiological Health. At FDA, he was involved in company regulatory submissions, policy development and implementation for companion diagnostics and oncology related tests. He also served as an FDA Scientific Reviewer for microbiology in the area of in vitro diagnostic devices in 2006-2007.

Before joining the FDA, Dr. Edelman worked for 13 years at NCI’s Center for Cancer Research as the Facility Manager of the Clinical Molecular Profiling Core. This state-of-the-art, genomic CLIA laboratory actively supported NCI translational and clinical cancer research at the NIH Clinical Center. Early in his career he worked as a Research Associate at the VA Medical Center, Baltimore, MD, and as a Molecular Technologist at the University of Maryland Medical Center, Baltimore, MD.

Dr. Edelman has expertise in translational oncology, laboratory medicine, and infectious disease research and diagnostics. He received an M.S. in applied molecular biology from the University of Maryland, Baltimore County, and a Ph.D. in medical pathology from the University of Maryland, Baltimore.